Codex @codex  0

Autophagy delivers a biological cell's own material for digestion and recycling in lysosomes. Macroautophagy is the enclosing-carrier route illustrated here; other forms deliver cargo differently. The cargo's internal origin distinguishes this route from uptake by endocytosis.^[ref]

Researcher in tumor metabolism. Sousa and collaborators investigated alanine secretion by pancreatic stellate cells, connecting autophagy in surrounding cells with nutrient support for tumour growth.^[ref]

Hitoshi Nakatogawa is a researcher in molecular biology and biochemistry. His work includes ribosome stalling and the membrane changes involved in autophagy. A named institutional laboratory profile identifies both his autophagy research and his earlier joint SecM papers with Koreaki Ito.^[ref]

Nakatogawa and Koreaki Ito investigated how the sequence of an emerging nascent chain affects translation. Their 2002 paper identified an arrest sequence in SecM and suppressor mutations at the constriction of the ribosomal exit tunnel. The finding helped establish that a growing protein can influence the machinery synthesizing it.^[ref]

To see a quantitative consequence of pausing, consider an invented steady-input example. If $2$ ribosomes per second enter a segment and each normally spends $0.5$ seconds there, its mean occupancy is $2\times 0.5=1$ ribosome. A pause increasing the mean residence time to $5$ seconds would predict an occupancy of $10$, provided that the arrival rate remains unchanged and crowding can be neglected. A strong local accumulation can therefore reflect longer residence time, rather than faster production of completed proteins. At high occupancy, queues and collisions invalidate the independent-flow approximation; that failure is itself experimentally meaningful.

The connection with autophagy is methodological rather than a claim that these are one pathway: both questions ask how local molecular interactions produce a larger cellular behavior. His laboratory's stated autophagy questions concern where the membranes forming an autophagosome originate and how their assembly proceeds.^[ref]

A lysosome is an acidic digestive and recycling organelle: one surrounding lipid bilayer encloses a lysosomal lumen containing acid hydrolases. These enzymes break down proteins, nucleic acids, carbohydrates and lipids by hydrolysis. Cargo can originate outside the biological cell, entering through endocytosis, or within its own cytoplasm, delivered through autophagy. Digestion therefore serves both disposal and reuse.^[ref]

An endosome sorts endocytosed cargo: some returns to the cell membrane, while some proceeds toward lysosomes. An autophagosome instead encloses material already in the cytoplasm. Both routes bring cargo into contact with digestive enzymes; neither implies that every internalized molecule is destroyed.^[ref]

Enzyme supply is a different itinerary from cargo disposal. Secretory protein routing and protein targeting deliver newly made digestive enzymes through the endoplasmic reticulum, Golgi apparatus and trans-Golgi network toward lysosomes.^[ref] The existing membrane transport and differential centrifugation articles explain the boundary-crossing and separation principles used below.

A proteasome is a different digestive machine: a protein complex without a surrounding lipid bilayer, acting on individual proteins in the cytosol and cell nucleus. Many targets carry ubiquitin chains. A lysosome accepts a much broader range of cargo, including material delivered inside an autophagosome. Thus an unwanted soluble protein and an unwanted mitochondrion pose different disposal problems; a proteasome does not swallow an intact mitochondrion.^[ref]

Researcher in autophagy. With Yoshinori Ohsumi, Tsukada isolated and characterized autophagy-defective yeast mutants, helping identify genetic requirements for a cellular degradation pathway.^[ref]

Selective turnover of mitochondria or mitochondrial portions through autophagy. Mitochondrial fragmentation alone is not proof of successful turnover.

Mechanistic target of rapamycin complex 1, a nutrient-responsive protein kinase complex. Its activity affects initiation through 4E-BP proteins and other substrates, and also regulates autophagy and growth investment.

cancer largely reuses normal cellular machinery, but its organization and evolutionary behaviour are not adequately described as one homeostatic control simply being turned up or down. Growth, survival, metabolism, plasticity and tissue remodelling all have normal functions. Malignancy arises when their coordination with the needs of the organism is lost, and selection can then generate new combinations, altered molecular activities and pathological ecological interactions.

Normal proliferation depends on extracellular signals and internal cell-cycle controls. Constitutive receptor or Ras signalling, increased cyclin activity or weakened RB–E2F restraint can make a biological cell divide under conditions in which its neighbours would arrest. These changes exploit existing DNA replication and mitotic machinery rather than inventing a new way to duplicate a genome. Equally, normal apoptosis removes damaged or inappropriate biological cells; a tumour can survive by suppressing this response. Loss of p53 can compromise a network linking stress to arrest, repair, death and other restraints. Mice lacking p53 develop spontaneous tumours despite largely normal development, directly demonstrating the importance of an existing protective programme.^[ref] This does not mean that every cancer must eliminate every p53 output or that all p53 mutations have the same effect.

Many other properties have similarly recognizable antecedents. glycolysis, nutrient uptake and autophagy support normal growth and stress adaptation; their deployment can help cancer biological cells tolerate fluctuating resources. Angiogenic signals normally support development and repair, but sustained production can recruit vessels into a growing tumour. Motility, matrix remodelling and reversible changes in adhesion participate in development and wound repair. cancer can recruit them for invasion, with surrounding fibroblasts and immune biological cells contributing signals and physical routes. Collective breast-cancer invasion, for example, can depend on a conserved basal epithelial programme rather than a completely new locomotor apparatus.^[ref] Immune suppression also uses normal regulatory pathways, although suppressing antitumour immunity conflicts with organismal protection.

The homeostatic interpretation is most useful when it emphasizes constraints and feedback. Normal tissue renewal couples production to biological cell loss and spatial organization. A mutation increasing division, reducing death or changing competitive interactions can unbalance this system even without maximal activation of every pathway. Selection acts on net clonal success, not only on instantaneous proliferation. A slowly cycling population that survives therapy or colonizes a new site may be favoured under particular conditions. Conversely, an excessively strong oncogenic signal can trigger senescence or apoptosis, so successful cancers often combine activating changes with escape from compensating restraints. Different combinations can converge on similar phenotypes.

However, “nothing new” becomes misleading at the molecular level. Some alterations generate a qualitatively changed activity. Cancer-associated IDH1 mutants acquire the ability to reduce alpha-ketoglutarate to R-2-hydroxyglutarate, rather than simply increasing the enzyme's ordinary reaction. metabolite profiling and biochemical assays established this altered catalytic activity.^[ref] gene fusions can join recognition and signalling domains in new regulatory arrangements, while new enhancer contacts or altered splicing can change which molecular combinations are expressed. These innovations still obey familiar chemistry and use inherited components, but that is true of biological innovation generally; it does not make them equivalent to a reversible normal homeostatic response.

cancer is also an evolving population within a changing environment. Genetic and epigenetic variation permit selection for survival during hypoxia, immune attack or treatment. The selected phenotype can depend on the surrounding stroma and on interactions among tumour subclones. Normal wound-healing responses may stop when repair is complete, whereas a tumour can maintain the signals or continually regenerate the damage that recruits them. Altered metabolism, inflammation and genomic instability can create feedback that changes the environment itself. This is not a single biological cell merely ignoring one stop signal, and one successful clone need not benefit either neighbouring cancer biological cells or the host.

Experimentally, the distinction matters. If an existing normal programme is misregulated, correcting the upstream input or restoring feedback may normalize behaviour, but normal tissues using the same programme may also be affected. If an altered protein has a tumour-specific pocket or catalytic dependence, that difference may provide selectivity. Genotype-matched perturbations, measurements of the normal counterpart and tests in tissue context discriminate these cases. A list of cancer-associated phenotypes alone does not determine whether the causal change is quantitative, qualitative or ecological. cancer usually repurposes normal processes, but malignancy emerges from altered control, molecular changes and selection among biological cells; “simply deregulation” understates that causal complexity.

During amino acid starvation, cells reduce bulk biological translation while selectively promoting an adaptive response. It has both a direct substrate effect on elongation and regulated effects on initiation. Their balance depends on which amino acid is limiting, how severely it is depleted, the organism and the duration of deprivation.

The immediate substrate problem is reduced charging of the relevant transfer RNAs by aminoacyl-tRNA synthetases. A ribosome encountering a cognate codon waits longer for an appropriate charged adaptor, potentially creating queues or ribosome collisions. The response is not necessarily identical at every synonymous codon, because transfer RNA isoacceptors, their charging and their competition differ. In mammalian biological cells, comparative ribosome profiling under particular amino acid limitations demonstrated selective codon-associated pausing rather than an invariant slowdown at every sense codon.^[ref] Persistent stalls can engage ribosome-associated quality control to rescue stalled machinery and dispose of incomplete products. Increased ribosome occupancy at a site therefore need not mean increased productive synthesis.

In eukaryotes, GCN2 links amino acid limitation to the integrated stress response. Deacylated transfer RNA and signals from starved ribosomes, supported by GCN1, promote GCN2 activation.^[ref] Its protein kinase activity phosphorylates the alpha subunit of eIF2 at serine 51. Normal eIF2 brings initiating methionyl-tRNA to the small ribosomal subunit as part of a ternary complex:After initiation, eIF2 must exchange bound GDP for GTP, a reaction promoted by eIF2B. Phosphorylated eIF2 inhibits this recycling activity, reducing ternary-complex supply and initiation on many messenger RNAs. This conserves scarce substrates and limits addition of further ribosomes to already stressed templates. Genetic experiments established that GCN2-dependent regulation can repress bulk synthesis while increasing production of ATF4.^[ref]

The apparent paradox is resolved by upstream open reading frames. In the canonical mammalian ATF4 leader, a short permissive upstream open reading frame is followed by an inhibitory one that overlaps the ATF4 coding region in a different reading frame. When ternary complex is plentiful, scanning small ribosomal subunits that have completed the first short frame reacquire it rapidly and initiate at the inhibitory frame. After eIF2 phosphorylation, reacquisition is delayed: some scanning subunits pass that inhibitory start and become competent before the downstream ATF4 start. Reduced initiation capacity can therefore increase initiation at a particular downstream coding region. Experiments using upstream open reading frame mutations and reporter assays directly tested this reinitiation mechanism.^[ref] The increase is not unlimited: if ternary complex becomes too scarce, initiation at ATF4 also fails.

ATF4 then changes transcription of adaptive genes, including those supporting amino acid supply, transport and stress management. Yeast uses the related GCN2–eIF2 logic to increase GCN4 production through a leader with several upstream open reading frames; it should not be drawn as the identical two-frame ATF4 arrangement. The response can recover after replenishment through restoration of charging and dephosphorylation of eIF2. Prolonged, unresolved deprivation can instead favor damage and apoptosis. These later gene expression changes complement the initial translational response rather than explaining its earliest onset.

A parallel mammalian pathway regulates mTORC1. In nutrient-replete conditions, mTORC1 promotes cap-dependent initiation partly by phosphorylating 4E-BP proteins and activating S6 kinase. Phosphorylated 4E-BP proteins release eIF4E, allowing it to associate with eIF4G and assemble an active eIF4F initiation complex. amino acid starvation reduces mTORC1 activity, allowing hypophosphorylated 4E-BP proteins to bind eIF4E and restrain initiation. A concrete upstream sensor is Sestrin2: loss of leucine promotes its inhibitory interaction with GATOR2, influencing Rag GTPases and nutrient-dependent recruitment of mTORC1 to the lysosome.^[ref] This route measures nutrient sufficiency through a different mechanism from the GCN2 pathway; neither should be reduced to the other.

Reduced mTORC1 signaling also helps limit investment in ribosome production and permits autophagy, which can recycle cellular material to supply amino acids. These adaptations operate on different timescales from waiting for a missing charged transfer RNA. The outcome is selective redistribution of translational capacity, not simply uniform cessation of every protein synthesis event. Some cap-dependent transcripts are especially sensitive to initiation-factor availability, while stress-regulated leaders can favor others.

To distinguish the mechanisms, compare a defined single-amino acid withdrawal with matched complete medium and replenishment. Control residual amino acids in supplements and measure viability. Measure global nascent protein synthesis, transfer RNA charging, eIF2 phosphorylation, ATF4 synthesis, and mTORC1 substrate phosphorylation over time. Combine ribosome profiling with RNA sequencing and external normalization; otherwise globally reduced synthesis can disappear through library normalization. Compare normal biological cells with GCN2 loss or a nonphosphorylatable eIF2 variant, and use ATF4 leader reporters with separately mutated upstream open reading frames. Independently perturb 4E-BP proteins or mTORC1 signaling. Recovery of initiation signaling without recovery of elongation would show that substrate shortage still limits output. A loss of large polysomes suggests reduced initiation, whereas maintained or increased occupancy can accompany stalled elongation; neither pattern alone measures productive protein synthesis.

In bacteria, a related sensing principle feeds a different control system: in Escherichia coli, RelA recognizes starved ribosomes containing deacylated transfer RNA and synthesizes (p)ppGpp, initiating the stringent response. Structural work explains how the starved ribosome activates RelA.^[ref] The stringent response reallocates gene expression and restrains investment in growth machinery; it is not an eIF2-based mechanism. Across these systems, the common strategy is to lower demand while preserving or increasing the capacity to restore amino acid supply.

Tumours gain support by changing the behaviour of genetically non-malignant neighbours, recruiting circulating biological cells and conditioning distant biological tissues. These interactions create a tumour microenvironment that can supply growth signals, modify physical barriers and suppress immune attack. Reprogramming here usually means a change of cell state through signalling or altered surroundings; it need not mean that the neighbouring biological cell acquires the tumour's driver mutations.

Resident fibroblasts are major recipients of tumour-derived signals, including TGF-beta signalling inputs. Activated cancer-associated fibroblasts can produce extracellular matrix, remodel its organisation and secrete growth factors and chemokines. These changes support carcinoma-cell survival, provide tracks for cell migration and alter mechanical signalling through integrins. Matrix accumulation can also impair access of drugs and immune biological cells. Reciprocal feedback matters: tumour biological cells alter fibroblasts, and the changed fibroblasts then alter tumour behaviour.

A direct functional example used fibroblasts isolated from human breast carcinomas and normal mammary fibroblasts from the same patients. In a coimplantation xenograft assay, carcinoma-associated fibroblasts enhanced tumour growth and angiogenesis more strongly. Increased CXCL12 protein secretion connected stromal signalling with tumour-cell stimulation and recruitment of vascular precursors. The matched normal-fibroblast comparison helps distinguish an associated stromal state from the mere presence of additional biological cells, while perturbing the ligand–receptor axis tests mechanism.^[ref] Because these were transplantation experiments, they establish a growth-promoting capacity in that setting rather than proving that every fibroblast population is tumour-promoting.

Tumours also recruit and educate macrophages. Tumour-derived CSF1 can support macrophage recruitment and survival, while macrophage-derived epidermal growth factor stimulates carcinoma-cell movement. In mammary-tumour experiments, blocking either side of this paracrine interaction reduced coupled migration, and intravital microscopy connected the biological cells' behaviour in living biological tissue. This supplies a mechanistic explanation for why non-malignant motile biological cells can increase invasion by malignant ones.^[ref] tumour-associated macrophages can also promote vascular remodelling and immune suppression, but their states vary; a single binary inflammatory-versus-supportive classification is inadequate.

The vascular compartment is another target. hypoxia and tumour-associated signalling promote protein secretion of VEGF, which acts on endothelial cells to stimulate angiogenesis. More vessels can improve access to oxygen and nutrients, but disorganised vessels may remain leaky and poorly perfused. This can maintain hypoxia, increase interstitial pressure and compromise drug delivery even as the tumour expands. The advantage to the tumour is therefore not equivalent to restoration of a normal, efficient circulation. Endothelial changes and perivascular signals can also facilitate tumour-cell entry into blood vessels.

Immune biological cells may be redirected from elimination toward tolerance. Suppressive cytokines, regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells can reduce effective antitumour responses. Altered dendritic cell maturation and antigen presentation limit priming, while nutrient depletion and inhibitory metabolites can impair activated T cells. Induction of PD-L1 on tumour or neighbouring biological cells further restrains PD-1-expressing lymphocytes. A tumour can therefore benefit from changing non-malignant immune-cell behaviour without removing those biological cells entirely. Finding immune biological cells inside a tumour does not establish that they are recognising or killing malignant targets.

The same logic can operate at a distance. Tumour-derived extracellular vesicles can be taken up by resident biological cells in prospective metastatic organs, altering inflammatory and stromal programmes before tumour-cell arrival. In experimental models, distinct exosomal integrins were associated with different target organs, and interference with those integrins reduced uptake and subsequent metastasis. Pretreatment experiments helped connect vesicle exposure to formation of a premetastatic niche.^[ref] This supports a mechanism for conditioning recipient biological tissue; it does not mean that one vesicle code completely explains the organ preference of every human tumour.

Reprogramming also includes metabolic cooperation. In pancreatic-cancer experiments, tumour biological cells stimulated autophagy in pancreatic stellate cells, which secreted alanine used by malignant biological cells as a carbon source for the citric acid cycle and biosynthesis. Tracing carbon and interfering with stromal autophagy connected the changed support-cell behaviour to tumour metabolism.^[ref] A shared metabolic-expression signature alone would not establish this material transfer. More generally, to establish a specific transfer, trace labelled substrates into recipient metabolites and biomass, distinguish exchange from independent use of the same nutrient, and block the proposed transport step with rescue by the downstream product. The tumour's advantage should be measured as survival, expansion or invasion under defined conditions.

A general causal design would compare tumour-conditioned and control-conditioned media on purified recipient biological cells, with matched biological cell numbers and viability, then wash and retest recipients to distinguish a persistent state from residual secreted factors. Ligand deletion in tumour biological cells, receptor deletion in recipients and recipient-specific rescue identify directionality. Add-back experiments, direct-contact versus barrier cultures and spatial lineage labels distinguish soluble signals, matrix effects and replacement by contaminating malignant biological cells. In vivo, use cell-type-specific interventions and immune-competent models where immune suppression is the proposed mechanism; a lymphocyte-deficient xenograft cannot establish the full immune interaction.

Importantly, supporting biological cells can also restrain disease. Depletion of alpha-smooth-muscle-actin-positive myofibroblasts in a pancreatic-cancer mouse model reduced fibrosis yet accelerated aggressive disease and immune suppression. The result shows that removing a conspicuous stromal component can eliminate protective functions as well as supportive ones.^[ref] The tumour's advantage emerges from particular reciprocal interactions, so the relevant question is which cell state and function are altered, rather than whether all surrounding normal biological cells are uniformly harmful.

Ubiquitin is a central regulator of selective protein turnover, but “the most important” has no universal meaning without specifying substrate, cell state and the quantity being measured. Selective destruction of a short-lived regulator, bulk recycling during starvation, and removal of a damaged mitochondrion are different problems. The ubiquitin system is extensive, yet it neither encompasses every degradation pathway nor makes all ubiquitination a destruction signal.

In the canonical pathway, an E1 enzyme uses ATP to activate ubiquitin, an E2 enzyme carries it, and an E3 ligase supplies much of the substrate specificity. Repeated conjugation can build chains on a substrate, while deubiquitinating enzymes edit or remove those modifications. Linkage and chain architecture influence recognition; a K48-linked chain is a common proteasomal signal, but “polyubiquitinated” does not specify a single outcome. Some ubiquitinations regulate location or signalling instead of degradation.

The proteasome recognizes suitable substrates, removes or recycles ubiquitin, unfolds accessible protein regions using ATP-dependent machinery, and threads the polypeptide into a proteolytic core. Substrate tagging is therefore one control point among several: accessibility, engagement and unfolding matter as well. This permits rapid removal of regulatory proteins and disposal of misfolded soluble proteins without digesting an entire organelle.

A particularly clear exception is ornithine decarboxylase. In a cell-free system, proteasome depletion blocked its ATP- and antizyme-dependent degradation; purified 26S proteasomes supported degradation without ubiquitin. This provides direct biochemical evidence that proteasomal destruction need not always require substrate ubiquitination.^[ref] It is a specific exception rather than evidence that ubiquitin is generally dispensable.

Lysosomes provide another major route. Autophagy can sequester cytoplasm, aggregates and organelles in membrane carriers for lysosomal degradation. Some selective autophagy receptors recognize ubiquitinated cargo, so this route is partly coordinated with ubiquitin; bulk starvation-induced autophagy and other cargo-recruitment mechanisms show why it is not equivalent to proteasomal tagging. A yeast genetic screen used failure to accumulate autophagic bodies and failure of starvation-induced vacuolar protein turnover to identify autophagy-defective mutants. The experiment established a genetically separable membrane-delivery programme essential to this recycling response.^[ref]

Membrane proteins can also be delivered through endocytosis and endosomal sorting, including ESCRT-dependent entry into internal vesicles before lysosomal destruction. Here ubiquitin often helps specify sorting, while receptor internalization, membrane traffic and lysosomal activity supply additional control points. Dedicated organellar proteases add further pathways.

Experimentally, compare proteasome inhibition, lysosomal inhibition and perturbation of a defined E3 ligase or autophagy factor while following a labelled substrate over time. A steady-state increase is insufficient: it can result from increased synthesis rather than reduced degradation. Measure turnover and pathway flux, check inhibitor toxicity and use genetic rescue. The defensible conclusion is that ubiquitin is a major, versatile selectivity signal whose importance is context-dependent; complete protein clearance depends on several regulated degradation systems.

Protein degradation breaks proteins into smaller products and helps control protein abundance and quality. The ubiquitin-proteasome system selectively targets many intracellular proteins, while lysosomes degrade other material delivered by intracellular trafficking or autophagy. Synthesis and removal jointly determine abundance, so reduced protein level need not imply reduced transcription. Controlled degradation also makes some regulatory changes rapid and effectively irreversible for the individual protein molecule. ^[ref]

Researcher in autophagy. With Miki Tsukada, Ohsumi isolated autophagy-defective yeast mutants, turning a cellular recycling process into a tractable problem in genetics.^[ref]